drug dosage
Exclusion of Drug
drug-developers
causaltive drug
iDILI cause
dilemma of iDILI
Idiosyncratic Drug induced Liver injury
late stage failures
individual patients
susceptible patients
majority of patients
novel test
innovative test
field of iDILI research
incorrect market withdrawals
incorrect terminations
late stage clinical phases
liver cell
liver transplantation
valid test available
pharmaceutical industry
regulatory bodies
MetaHeps GmbH
project terminations
USD
high volume clinical trial market
Patient Blood Samples
Overall objective of DILITEST
novel saftey biomarkers
innovative treatment options
validation
independent cohorts of european
american registries
international experts
death
customers
marketing of safe drugs
unrivaled technology
focus
service
hundreds of millions
latency
serious consequences
investment losses
major causes
significant challenge
cells
need
patented method
possibility
animal testing
Diagnosis